Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. - Wikidata - wikimedia - TriplyDB

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

http://www.wikidata.org/entity/Q47635702

about

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma Novel agents in the treatment of multiple myeloma: a review about the future The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective The role of maintenance therapy in multiple myeloma Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.The next generation of novel therapies for the management of relapsed multiple myeloma.The role of SLAMF7 in multiple myeloma: impact on therapy.Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.Immunotherapy in hematologic malignancies: past, present, and future.Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma.Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.Carfilzomib boosted combination therapy for relapsed multiple myeloma Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Posttransplant maintenance therapy in multiple myeloma: the changing landscape.Pomalidomide-dexamethasone in refractory multiple myeloma: Long-term follow-up of a multi-cohort phase II clinical trial.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Novel investigational drugs active as single agents in multiple myeloma.Immunologic approaches for the treatment of multiple myeloma.Which therapies will move to the front line for multiple myeloma?Highlights of Multiple Myeloma at the Annual Meeting of American Society of Hematology, 2016.The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.An update on the role of daratumumab in the treatment of multiple myeloma.How is patient care for multiple myeloma advancing?Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.The safety of daratumumab for the treatment of multiple myeloma.A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.New developments in the treatment of multiple myeloma - clinical utility of daratumumab.Daratumumab for the treatment of multiple myeloma.Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.

P2860

Q26745919-6275852C-1211-4527-8045-1BC613E5CF78 Q26745924-DAF93AAA-E1C3-46E4-8AC4-A6BB5756673B Q28069789-21E979BE-23F0-464E-87F4-4B89C00F1B84 Q28071644-A70C4B23-910A-49DD-B317-0928E3476B6A Q28075816-FFBBA016-5C16-458C-85B9-BCD3204814DF Q30238893-CB0A5438-CA09-4616-B61D-928390BE5988 Q30248534-0B950055-ABB7-439D-BE33-68412F38802E Q30249167-ECA356B1-E66D-442E-9B18-8BE94E5476B8 Q31119290-8D39AF63-0DA5-44F0-B327-59594506DA21 Q33432492-3D3DDB07-CC8C-4161-8DFF-27256B22F7AD Q33434683-49DA56DE-F778-4A86-86D4-1900C64A2558 Q33437691-A1CCD9F5-204A-4871-B51D-1A276E3A822F Q33439437-1BC7B732-D6B5-4FE6-B729-DC99D4207193 Q33441476-67A919A8-AE77-4694-9F2B-3AF0FD24881C Q33593865-3686EEBE-1681-467B-9743-66C430311E4C Q34551324-40E55AE3-9935-44CC-B23D-568C73C571D8 Q34556156-2B88390E-555B-4F7F-AA7F-DCD0F71392FF Q36363958-6E4B35F4-1E73-4DB2-BFC5-1695733A0DE8 Q37076421-BCBACB9A-BFE1-4837-9326-C51B851A77B0 Q37517482-2C1336BC-981F-4C3C-8647-B7762028F196 Q37593573-5D88C256-4027-44B9-B054-63F58640950F Q37652953-114E1B7F-02F7-4FA3-B30A-68CB2D3605E8 Q37687119-0B92BC0E-9213-4942-8CD7-FA9BCBE7C375 Q37697253-A603D9DB-30A0-4E92-AB2A-BB633168B14E Q37737800-467E0623-BC90-4537-8235-EB85AA32C2A3 Q38599023-51A6C3BD-A563-4CBD-9BCA-F301209B032C Q38672091-6720F6BD-D240-45CE-90F8-4B2859B6E4B1 Q38690290-17228175-281D-48E6-8493-1FC62492E26A Q38692244-F8DED8DE-F129-4476-9813-67D772E8D1E3 Q38733592-D3243723-737E-4FDF-9385-F24DC47E3C80 Q38735228-4ACE3E32-D082-4B4F-B8B6-34F5FA82601C Q38745915-EBDBE03B-000F-467F-8ADA-DBE327C0D985 Q38775700-2606CCAC-14A8-4289-B5C2-57F17A529F36 Q38786149-A089D42A-08AD-46C5-AFC7-1E8253A1B469 Q38792725-96F2149E-9C19-4FB6-ABD6-88EB4DF917A8 Q38793959-D65CD5BC-12E7-480C-A08E-323B7E71E70C Q38797097-94924CFE-4564-404A-8870-009869560361 Q38820002-A0D24654-EB61-4BA8-9FA8-E3C4316051B0 Q38824538-F6D93ED8-4455-4788-B73C-D4E9BD54865F Q38853857-057A888F-5843-495D-A8A8-850A6F7768F0

P2860

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

http://www.wikidata.org/entity/Q47635702

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Daratumumab monotherapy in pat ...... el, randomised, phase 2 trial.

@en

Daratumumab monotherapy in pat ...... el, randomised, phase 2 trial.

@nl

type

label

Daratumumab monotherapy in pat ...... el, randomised, phase 2 trial.

@en

Daratumumab monotherapy in pat ...... el, randomised, phase 2 trial.

@nl

prefLabel

Daratumumab monotherapy in pat ...... el, randomised, phase 2 trial.

@en

Daratumumab monotherapy in pat ...... el, randomised, phase 2 trial.

@nl

P1433

Q47635702-D2EFDD3B-A7E8-43D3-9EC2-AD17C7296E64

P1476

Q47635702-0DD57036-6EEB-4A09-8EFD-271B26EEE065

P2093

Q47635702-028F2A63-AE27-4BA4-8686-C85C1C9A195C

Q47635702-188CE0C4-CCB5-49AD-833E-D93A7342B1DF

Q47635702-215FA448-7549-4C5D-82E6-B0AA78ECD178

Q47635702-2381B65C-8651-4DF5-AD8C-791EEEDEBE22

Q47635702-2908AEB8-60C5-4459-8022-A5B7D8C83BCE

Q47635702-2C26F068-C672-42F1-B870-D5C15018A52F

Q47635702-3CD5DE38-E841-4E8A-B0DE-434E6CFB76A8

Q47635702-4A540F4A-8C4A-422A-AB34-8FF7C42A16D0

Q47635702-532D1F14-D396-48F6-B9B5-70BAB42C5DEA

Q47635702-61CC5C08-3F10-44AD-98D1-0682084CAFEE

P304

Q47635702-5C2E42B8-DD3A-4A1F-8920-A6F72D6DBDCA

P31

Q47635702-8C7A6F44-BBA9-49B4-8054-7135A2788875

P356

Q47635702-0DE269E2-B7FF-4B51-BDAB-BC775B8CB254

P407

Q47635702-57529D84-9C91-4D99-A78C-080F22C5E430

P433

Q47635702-F5F62F39-A7A2-45EB-9DA3-1335B50437CD

P478

Q47635702-3445614D-7118-4E4E-9D5C-2AE523F70A25

P50

Q47635702-86A200C5-1343-4B13-B5C2-447BA8DBC802

Q47635702-8A8D50AB-2CC8-4DE4-9175-F57F72980700

Q47635702-D656F388-C8FF-44A4-ABF6-D3E26E6A58EE

Q47635702-E93ECC89-C243-4C74-823B-F5FD81FFC06E

Q47635702-F16134EC-B37F-4088-B38F-F4A6C1ECD361

P577

Q47635702-7EDAC809-0501-4B3A-9276-CEB4B723C242

P698

Q47635702-781EB789-62F0-403E-BFF8-9739F5BA32C8

P921

Q47635702-46184BEA-1418-4FAB-B4DD-F7663D7FFB1E

P356

S0140-6736(15)01120-4

P1433

P1476

Daratumumab monotherapy in pat ...... el, randomised, phase 2 trial.

@en

P2093

Ajai Chari

http://www.w3.org/2001/XMLSchema#string

Amitabha Mazumder

http://www.w3.org/2001/XMLSchema#string

Amrita Krishnan

http://www.w3.org/2001/XMLSchema#string

Andrew Belch

http://www.w3.org/2001/XMLSchema#string

Andrzej Jakubowiak

http://www.w3.org/2001/XMLSchema#string

Brendan M Weiss

http://www.w3.org/2001/XMLSchema#string

Clarissa M Uhlar

http://www.w3.org/2001/XMLSchema#string

Darrell White

http://www.w3.org/2001/XMLSchema#string

Don A Stevens

http://www.w3.org/2001/XMLSchema#string

Emma C Scott

http://www.w3.org/2001/XMLSchema#string

P304

1551-1560

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(15)01120-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

10027

http://www.w3.org/2001/XMLSchema#string

P478

387

http://www.w3.org/2001/XMLSchema#string

P50

Javier de la Rubia

Paul G Richardson

Robert Z Orlowski

P577

2016-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26778538

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial